glp-1 heart failure Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology Gut Hormones in Heart Failure

Combining NAD with GLP-1 medications like Zepbound raises important questions about safety and efficacy

Pfizers dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron

delivery typically takes 510 business days from shipment

Explores the potential long-term side effects associated with GLP-1 medications and chronic constipation

Liquivida offers medically supervised GLP-1 weight loss injections